Live Attenuated Vaccines Market Size, Share & Trends Analysis Report By Product (Viral, Bacterial), By Disease Indication (Measles, Mumps, and Rubella (MMR), Varicella (Chickenpox), Influenza, Rotavirus, Yellow Fever, Polio, Others), By Route of Administration (Oral, Parenteral, Intranasal), By Age Group (Pediatric, Adult) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Market Overview

The global live attenuated vaccines market size was valued at USD 19,270.55 million in 2023. It is estimated to reach USD 26,784.59 million by 2032, growing at a CAGR of 3.9% during the forecast period (2024–2032).

A live attenuated vaccine is a type of immunization that uses a weakened form of the pathogen (virus or bacteria) responsible for the disease it aims to prevent. These vaccines are designed to replicate in the body without causing the full-blown disease, thereby stimulating a strong and long-lasting immune response. The attenuation process involves altering the pathogen in a laboratory setting to reduce its virulence while maintaining its ability to induce immunity. Live attenuated vaccines are highly effective because they closely mimic a natural infection, providing comprehensive and enduring protection against the targeted disease.

The Live Attenuated Vaccines (LAV) Market is experiencing robust growth driven by the increasing prevalence of infectious diseases and the strong emphasis on immunization programs worldwide. Advances in vaccine technologies, coupled with substantial funding from the government and private sectors for research in vaccines, are supporting innovation and development of new live attenuated vaccines. Furthermore, increased public awareness regarding vaccination requirement and activities related to the availability and distribution of the vaccines work as a great aid in helping to expand this particular market. This growth trajectory is further supported by the introduction of new delivery systems that improve vaccine efficacy and patient compliance, ensuring a steady demand for live attenuated vaccines across various demographics.

Market Dynamics

Global live attenuated vaccines market drivers:

Increasing prevalence of infectious diseases 

The main driver of live attenuated vaccines is the surging incidences of infectious diseases across the world. Outbreaks of measles and mumps have increased in different regions. As a result of this, public health agencies are striving to increase vaccination coverage. For instance, in the United States, in 2019, the number of measles cases was the highest in over 25 years. Unvaccinated communities were largely affected by this. Such instances underscore the critical need for effective vaccines, driving demand for live attenuated vaccines that offer strong and lasting immunity.

Advances in vaccine technology

Technological advances in the development and production of vaccines are propelling the live attenuated vaccines market. Innumerable innovations have been made in recombinant DNA technology and novel delivery systems to bring enhanced efficacy and safety profiles of vaccines. For instance, the oral poliovirus vaccine, due to its ease of administration and strong immune response elicited after administration, revolutionized the polio eradication program. Such technological development continues to fuel the live attenuated vaccines market growth, as now more potent and easily created vaccines can be created.

Global live attenuated vaccines market restraint:

High costs of vaccine development and production

The development and production of live attenuated vaccines are associated with high costs, which can restrain market growth. The complex process of attenuating live pathogens, ensuring their safety and efficacy, and complying with stringent regulatory requirements demands significant financial investment. For instance, the development of the live attenuated dengue vaccine, Dengvaxia, by Sanofi took over 20 years and an estimated $1.5 billion. Such high costs can limit the number of companies willing to invest in live attenuated vaccine development, thereby restraining market expansion.

Global live attenuated vaccines market opportunities:

Public-private partnerships for vaccine distribution

Government, NGOs, and private companies are becoming increasingly involved in collaborative efforts that improve the distribution and accessibility of live, attenuated vaccines. The Gavi, Vaccine Alliance, represents an initiative between the public and private sectors to improve vaccine coverage in low-income countries. In 2020, Gavi supported the distribution of millions of doses of live, attenuated vaccines to some of the poorest countries in the world. These partnerships can facilitate large-scale vaccination programs and contribute extensively to the market by ensuring that vaccines are supplied to needy populations.

Development of new live attenuated vaccines for emerging infectious diseases

New developments of live, attenuated vaccines against emerging infectious diseases offer strong potential for growth. Once more, this pandemic of COVID-19 has brought to the forefront the need for the development of vaccines in short periods of time and the timely deployment of the same. Accordingly, companies and research centers are field-testing live, attenuated vaccine candidates for COVID-19, Zika, and Ebola. For instance, the experience of Codagenix engineering a live attenuated COVID-19 vaccine in cooperation with India's Serum Institute of India illustrates this technology's potential to contribute to fighting new public health threats. Successful launches of vaccines could open up totally new markets with new uses, compel further innovation, and expand the market demand.

Regional Analysis

Based on region, the global live attenuated vaccines market share is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

North america dominates the global market

North America is the most significant shareholder in the global live attenuated vaccines market due to its advanced healthcare infrastructure, high immunization coverage, and substantial government support for vaccination programs. The presence of leading vaccine manufacturers, ongoing research and development activities, and strong public awareness about the importance of vaccination further bolster the market in this region.

The United States is a major player in the live attenuated vaccines market due to its advanced healthcare infrastructure, robust research and development capabilities, and significant government support for vaccination programs. The country has a well-established framework for vaccine approval and distribution, facilitated by agencies like the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC).

Canada plays a significant role in the live attenuated vaccines market, characterized by its strong public health system and widespread immunization programs. The country prioritizes vaccination as a critical component of its healthcare policy, supported by federal and provincial health authorities. Programs such as the National Immunization Strategy aim to ensure high vaccine coverage across the population, particularly for preventable diseases like measles, mumps, and rubella.

These factors are estimated to drive the North American market growth.

Asia-Pacific region is a pivotal market for the live attenuated vaccines industry, witnessing robust growth driven by rapid industrialization, urbanization, and economic development. The region's has large and diverse population with increasing incidence of infectious diseases, and growing public health initiatives.

China is a significant player in the global market, driven by its large population and strong government commitment to public health. The Chinese government has implemented extensive immunization programs, such as the Expanded Program on Immunization (EPI), which includes vaccines for measles, mumps, rubella, and other infectious diseases. China's robust biotechnology and pharmaceutical industry, supported by significant investments in research and development, contributes to the production and innovation of live attenuated vaccines.

India is a critical market for live attenuated vaccines due to its vast population and high burden of infectious diseases. The Indian government, through initiatives like the Universal Immunization Programme (UIP), provides free vaccines for various diseases, including measles, mumps, and rubella, to millions of children nationwide. The country's growing healthcare infrastructure, combined with efforts to increase vaccination rates and public awareness, supports the market's expansion.

Thus, the factors above are estimated to boost the Asia-Pacific live attenuated vaccines market growth.

Segmental Analysis

The global live attenuated vaccines market is segmented by product, disease indication, route of administration and age group.

Based on product, the global live attenuated vaccines market is divided into viral and bacterial. 

The viral vaccines segment dominates the global market. The main cause of this dominance is the prevalence and extensive effects of viral infections including measles, mumps, rubella, influenza, and varicella (chickenpox) on public health. Particularly in youngsters, these highly contagious viral infections can cause serious morbidity and mortality. As a result, there is a great need for efficient vaccination against these viral diseases.

Based on disease indication, the global live attenuated vaccines market is bifurcated into Measles, Mumps, And Rubella (MMR), varicella (Chickenpox), influenza, rotavirus, yellow fever, polio and others. 

The Measles, Mumps, and Rubella (MMR) is estimated to own the market. This dominance is a result of the MMR vaccine's combined efficacy and all-encompassing protection, which treat three highly contagious viral diseases with a single shot. High vaccination rates are a result of widespread immunization campaigns and laws requiring childhood vaccination against the measles, mumps, and rubella in many nations.

Based on route of administration, the global market for live attenuated vaccines is segmented into oral, parenteral, intranasal. 

In the live attenuated vaccines industry, the parenteral route of administration dominates over oral and intranasal routes. The main cause of this dominance is injectable vaccines' extensive usage and demonstrated effectiveness in generating strong, long-lasting immunity against a range of infectious diseases. For vaccinations like varicella, yellow fever, and MMR (measles, mumps, and rubella), parenteral administration is the preferred method of administration. These vaccines are essential parts of national immunization programs with highest demand across the globe.

Based on age group, the market for live attenuated vaccines is bifurcated into pediatric and adult. 

In the live attenuated vaccines market, the pediatric segment dominates over the adult segment. The vital function that live attenuated vaccines play in early childhood immunization programs which prevent a variety of infectious diseases is what drives this dominance. Children receive vaccinations like varicella, rotavirus, and MMR (measles, mumps, rubella) as part of national and international immunization schedules to protect them against diseases that have high rates of transmission and can seriously complicate young people. The widespread implementation of these pediatric vaccination programs, supported by government policies and public health initiatives, ensures high coverage and compliance, making the pediatric segment the leading age group in the live attenuated vaccines market.

Recent Developments

• In November 2023, the FDA approved Valneva SE's single-dose live-attenuated vaccine, IXCHIQ, for chikungunya fever. With this launch, the vaccine sector saw the introduction of novel solutions and a new line of therapy for chikungunya.
• In May 2023, a contract was signed by IAVI and Biofabri, a Zendal subsidiary, for the full development of the tuberculosis vaccine candidate MTBVAC. Throughout the arrangement, IAVI provided support for the program's development, worldwide regulatory strategy, and resource mobilization. The collaboration is anticipated to improve global access to the tuberculosis vaccination.

Analyst’s Perspective:

As per our research analysts, the rising incidence of infectious diseases and the increased focus on global immunization programs are expected to fuel substantial expansion in the live attenuated vaccines market. The effectiveness and safety profiles of live attenuated vaccines are being improved by developments in biotechnology and vaccine research, making them the recommended option for avoiding a variety of diseases. The acceptance of vaccines is being supported by government programs, significant funding from the public and commercial sectors, and effective public health campaigns, particularly in emerging markets.